Larixyl acetate

Larixyl acetate is a potent and selective TRPC6 inhibitor with IC₅₀ values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction^{[1][2][3][4][5]}. In Vitro:Larixyl acetate (1-10 μM, 3 minutes) exerts its anti-inflammatory activity by inhibiting the phosphorylation of ERK1/2, AKT, and Src, suppressing fMLP-induced neutrophil migration, and inhibiting the interaction between βγ subunits and Src or PLCβ^[2].
Larixyl acetate (5 μM, 1 hour) effectively improves TBI-induced aortic endothelial dysfunction by inhibiting TRPC6 activity^[3].
Larixyl acetate (5 μM, 72 hours) significantly reduces the expression of ER stress genes and improves cell function in a cardiac hypertrophy cell model (H9c2 rat cardiomyocytes induced by Ang II)^[5].
In Vivo:Larixyl acetate (5 mg/kg, i.p., once dailly for 7 days) significantly improves aortic endothelial dysfunction in TBI mice by inhibiting TRPC6 activity, particularly enhancing acetylcholine-induced dilation^[3].
Larixyl acetate (5 mg/kg, i.p., once daily for 4 weeks) improves cardiac function in pressure overload-induced heart failure model by inhibiting TRPC6, reducing cardiac hypertrophy, fibrosis, and apoptosis^[4].